Relatively hopeful data from MARIO-3 (eganelisib, atezolizumab and nab-paclitaxel in 1L mTNBC. It has to be viewed cautiously as comparisons are made to historical population of IM130 but for now PI3K-gamma inhibition appears to be resurrected #TNBC #PI3Kgamma #EndCancer

https://www.businesswire.com/news/home/20221114005336/en/Infinity-Pharmaceuticals-Provides-MARIO-3-Update-in-Patients-with-Front-Line-Metastatic-Triple-Negative-Breast-Cancer-Suggesting-Potential-Long-Term-Patient-Benefit-of-Eganelisib